Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis - Université Claude Bernard Lyon 1 Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2016

Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis

Romain Magnez
Laurence Fonseca
  • Fonction : Auteur
Carole Vaysse
  • Fonction : Auteur
Leslie Couedelo
  • Fonction : Auteur

Résumé

Based on a previous study and in silico molecular docking experiments, we have designed and synthesized a new series of ten 5-Alkoxy-N-3-(3-PhenoxyPhenyl)-1,3,4-Oxadiazol-2(3H)-one derivatives (RmPPOX). These molecules were further evaluated as selective and potent inhibitors of mammalian digestive lipases: purified dog gastric lipase (DGL) and guinea pig pancreatic lipase related protein 2 (GPLRP2), as well as porcine (PPL) and human (HPL) pancreatic lipases contained in porcine pancreatic extracts (PPE) and human pancreatic juices (HPJ), respectively. These compounds were found to strongly discriminate classical pancreatic lipases (poorly inhibited) from gastric lipase (fully inhibited). Among them, the 5-(2-(Benzyloxy)ethoxy)-3-(3-PhenoxyPhenyl)-1,3,4-Oxadiazol-2(3H)-one (BemPPOX) was identified as the most potent inhibitor of DGL, even more active than the FDA-approved drug Orlistat. BemPPOX and Orlistat were further compared in vitro in the course of test meal digestion, and in vivo with a mesenteric lymph duct cannulated rat model to evaluate their respective impacts on fat absorption. While Orlistat inhibited both gastric and duodenal lipolysis and drastically reduced fat absorption in rats, BemPPOX showed a specific action on gastric lipolysis that slowed down the overall lipolysis process and led to a subsequent reduction of around 55% of the intestinal absorption of fatty acids compared to controls. All these data promote BemPPOX as a potent candidate to efficiently regulate the gastrointestinal lipolysis, and to investigate its link with satiety mechanisms and therefore develop new strategies to "fight against obesity".

Domaines

Chimie
Fichier principal
Vignette du fichier
Revised Manuscript - Point et al - EurJMedChem.pdf (1.21 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-01466841 , version 1 (06-12-2022)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Vanessa Point, Anaïs Benarouche, Julie Zarrillo, Alexandre Guy, Romain Magnez, et al.. Slowing down fat digestion and absorption by an oxadiazolone inhibitor targeting selectively gastric lipolysis. European Journal of Medicinal Chemistry, 2016, 123 (834-848), ⟨10.1016/j.ejmech.2016.08.009⟩. ⟨hal-01466841⟩
137 Consultations
38 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More